Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 1/20 | 0.43 |
| ▸ | MTTP | P55157 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 4/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493011 | 0.92 | MTTP (0.48) | APOBMTTPKITMCHR1SMO | |
| SCHEMBL6487402 | 0.90 | GCGR (0.41) | — | |
| SCHEMBL6499436 | 0.86 | RAB9A (0.46) | APOBMTTPKITKDRMAPK14 | |
| SCHEMBL6503526 | 0.85 | TRPV1 (0.43) | APOBMTTPKITKDRMCHR1 | |
| SCHEMBL6492232 | 0.85 | CYP3A4 (0.41) | APOBMTTPKDRRAB9A | |
| SCHEMBL6489566 | 0.84 | GCGR (0.43) | APOBMTTPKITMCHR1SMO | |
| SCHEMBL6487481 | 0.84 | F10 (0.43) | KITKDRLCKRAB9A | |
| SCHEMBL6499275 | 0.83 | MTTP (0.47) | APOBMTTPKITBTKMCHR1 | |
| SCHEMBL6492769 | 0.83 | P2RX1 (0.50) | KDRMCHR1SMO | |
| SCHEMBL6489781 | 0.82 | L3MBTL1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | APOB 1/4885MTTP 677/4885KIT 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.